You are here: Industry Insights > Vernalis

News List

HitGen to acquire Vernalis for $25 mn in cash expresspharma
October 14, 2020
The closing of this transaction is subject to customary conditions and approvals, expected to complete before the end of 2020.
Ligand Announces the Close of its Acquisition of Vernalis americanpharmaceuticalreview
October 12, 2018
Ligand announces that its acquisition of Vernalis has successfully closed and Vernalis will now operate as a subsidiary of Ligand. Vernalis is a structure-based drug discovery biotechnology company with a broad pipeline of partnered programs and ongoing c
Vernalis, weakened by FDA rejections, accepts £33M Ligand bid fiercebiotech
August 13, 2018
Ligand Pharmaceuticals is set to acquire Vernalis for the knockdown price of £33 million ($42 million). The takeover agreement comes one year after Vernalis was left reeling by a second FDA rejection in quick succession.
Ligand Makes Offer to Acquire Vernalis americanpharmaceuticalreview
August 10, 2018
Ligand Pharmaceuticals and Vernalis announced that Ligand has declared its firm intention to acquire the entire issued and to be issued shares of Vernalis.
Vernalis, Daiichi Sankyo work together on new cancer targets pharmatimes
December 14, 2017
UK drugmaker Vernalis has signed a drug discovery deal with Daiichi Sankyo Co that aims to find new targets for potential cancer therapies.
FDA rejects second Vernalis cough/cold treatment pharmatimes
August 08, 2017
The US Food and Drug Administration has rejected Vernalis’ cough cold treatment CCP-08, which is being developed by US partner Tris Pharma.
Vernalis cough and cold drug knocked-back by FDA pharmafile
August 08, 2017
Vernalis has been given a second CRL for a cough and cold treatment by the FDA this year. The therapy, known as CCP-08, has fallen foul of the issues that led to CCP-07 being rejected earlier this year, in April.
Vernalis and Servier sign oncology drug discovery collaboration pharmaceutical-technology
March 08, 2017
UK-based Vernalis and French pharmaceutical company Servier have entered a new oncology drug discovery collaboration.